The FDA grants a priority review designation to Exelixis' (EXEL +8.6%) cabozantinib treatment...


The FDA grants a priority review designation to Exelixis' (EXEL +8.6%) cabozantinib treatment for medullary thyroid cancer and set an action date of November 29. In preclinical studies, cabozantinib killed tumor cells, lowered metastases, and inhibited the formation of the new blood vessels needed to support tumor growth. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs